This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localized manufacturing in one of the world’s fastest-growing medtech markets, states the company.

“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke. 

Related article

Who should lead the transformation towards sustainable healthcare?

With healthcare systems under unsurmountable pressure and patient care at risk, embracing a holistic approach to sustainable healthcare is critical to protecting the future of healthcare.

“Closer to our customers in China”

The manufacturing site, spanning 10,000 m2 is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027.

“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.